CL2008003305A1 - Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. - Google Patents
Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.Info
- Publication number
- CL2008003305A1 CL2008003305A1 CL2008003305A CL2008003305A CL2008003305A1 CL 2008003305 A1 CL2008003305 A1 CL 2008003305A1 CL 2008003305 A CL2008003305 A CL 2008003305A CL 2008003305 A CL2008003305 A CL 2008003305A CL 2008003305 A1 CL2008003305 A1 CL 2008003305A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation process
- excipients
- cancer
- optionally
- injectable composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
Composición inyectable que comprende al menos un ingrediente seleccionado de antipsicóticos, inhibidores de aromatasa, bloqueante adrenérgico alfa-1, inhibidores de acetilcolinesterasa, al menos un polímero bioerosionable biocompatible y un solvente no tóxico; proceso de preparación.Injectable composition comprising at least one ingredient selected from antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocker, acetylcholinesterase inhibitors, at least one biocompatible bioerodible polymer and a non-toxic solvent; Preparation process.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2321DE2007 | 2007-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003305A1 true CL2008003305A1 (en) | 2009-06-05 |
Family
ID=40626309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003305A CL2008003305A1 (en) | 2007-11-06 | 2008-11-06 | Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR070033A1 (en) |
CL (1) | CL2008003305A1 (en) |
WO (1) | WO2009060473A2 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1589901A4 (en) | 2002-12-20 | 2006-08-09 | Generipharm Inc | Intracutaneous injection |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
ES2390439B1 (en) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | INJECTABLE COMPOSITION |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
PL2394663T3 (en) * | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Compositions for injectable in-situ biodegradable implants |
ES2589106T3 (en) * | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Injection controlled antipsychotic composition |
US20120046225A1 (en) | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
CA2816203C (en) * | 2010-10-28 | 2017-02-21 | Transdermal Research Pharm Laboratories, Llc | Aripiprazole compositions and methods for its transdermal delivery |
EP2658525B1 (en) | 2010-12-29 | 2017-08-30 | Medincell | Biodegradable drug delivery compositions |
EP2683364B1 (en) | 2011-03-10 | 2017-01-18 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
CA2830511C (en) | 2011-03-18 | 2021-09-14 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate |
CA2853249A1 (en) | 2011-10-24 | 2013-05-02 | Endo Pharmaceuticals Solutions Inc. | Implantable tizanidine compositions and methods of treatment thereof |
CA2853277A1 (en) * | 2011-10-24 | 2013-05-02 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions and methods of treatment thereof |
CN103930096B (en) | 2011-10-31 | 2017-05-31 | Xeris药物公司 | Preparation for treating diabetes |
EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
NZ630703A (en) | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising glycerol esters |
ES2950418T3 (en) * | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
NZ631345A (en) | 2012-09-19 | 2017-06-30 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
WO2014160155A2 (en) * | 2013-03-14 | 2014-10-02 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof |
MA39495A (en) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Ltd | ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES |
AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
CN104189954B (en) * | 2014-09-19 | 2017-03-29 | 中国科学院长春应用化学研究所 | A kind of in-situ solidifying tissue engineering bracket and preparation method thereof |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
TWI718168B (en) * | 2015-08-03 | 2021-02-11 | 愛爾蘭商托爾瑪國際有限公司 | Liquid polymer delivery system for extended administration of drugs |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
FI3377041T3 (en) | 2015-11-16 | 2023-11-30 | Medincell S A | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
KR102033686B1 (en) | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | Microneedle transdermal patch comprising donepezil |
KR20240036128A (en) | 2017-06-02 | 2024-03-19 | 엑스에리스 파머수티클스, 인크. | Precipitation resistant small molecule drug formulations |
GB2568526A (en) * | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
PE20210047A1 (en) * | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | INJECTABLE COMPOSITION |
AR116501A1 (en) * | 2018-09-25 | 2021-05-12 | Tolmar Int Ltd | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED DRUG ADMINISTRATION |
US11911499B2 (en) * | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
CN113209370B (en) * | 2020-01-21 | 2023-11-28 | 渼颜空间(河北)生物科技有限公司 | Biodegradable injection filler, preparation method and application thereof |
EP4362932A1 (en) * | 2021-06-30 | 2024-05-08 | The University of North Carolina at Chapel Hill | Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery |
WO2023116517A1 (en) * | 2021-12-24 | 2023-06-29 | 四川科伦药物研究院有限公司 | Continuous delivery preparation capable of being stably released and preparation method therefor |
US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69735384T2 (en) * | 1996-12-20 | 2006-08-10 | Alza Corp., Mountain View | Gel compositions and methods |
US7128927B1 (en) * | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
EP1824460B1 (en) * | 2004-11-10 | 2014-12-24 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
MX2009003737A (en) * | 2006-10-05 | 2009-06-16 | Panacea Biotec Ltd | Injectable depot composition and it's process of preparation. |
-
2008
- 2008-11-06 WO PCT/IN2008/000757 patent/WO2009060473A2/en active Application Filing
- 2008-11-06 CL CL2008003305A patent/CL2008003305A1/en unknown
- 2008-11-06 AR ARP080104860A patent/AR070033A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009060473A2 (en) | 2009-05-14 |
AR070033A1 (en) | 2010-03-10 |
WO2009060473A3 (en) | 2009-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003305A1 (en) | Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer. | |
BRPI0916235A2 (en) | compound, pharmaceutical composition, use of the compound or composition, and method for treating an hcv infected patient | |
MX361467B (en) | Isoindoline compounds for use in the treatment of cancer. | |
ES2526606T3 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
ECSP088239A (en) | COMPOSITION OF SUSTAINED DRUG RELEASE | |
AR054227A1 (en) | COMPOSITION OF ACTIVE PRINCIPLES | |
CL2007003495A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED CONDENSED HETEROCICLES, INHIBITORS OF THE ACTIVITY OF THE AKT; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF CANCER. | |
PE20121555A1 (en) | COMBINATION OF A POLYPLOID INDUCING AGENT AND A Bcl-2 INHIBITOR | |
AR068195A1 (en) | COMPOSITIONS AND METHODS FOR SEED TREATMENT | |
AR047936A1 (en) | MANIFULATION RESISTANT TRANSDERMIC DOSAGE FORM | |
ECSP10010548A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
CL2007001869A1 (en) | COMPOUNDS DERIVED FROM BENCIMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES MODULATED WITH FXR AGONISTS, SUCH AS DISLIPIDEMIAS, DIABETES, CANCER, OSTEOPOROSIS AND E | |
CL2009000393A1 (en) | Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders. | |
CL2013001202A1 (en) | Method for preventing plant diseases comprising applying an agent for soil treatment, where the agent comprises compounds derived from quinoline or its salts as active ingredient. | |
BRPI0815057A2 (en) | Compound, pharmaceutical composition, and method for treating infection. | |
CL2007003557A1 (en) | COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. | |
CL2007003356A1 (en) | COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES. | |
CL2009001298A1 (en) | Compounds derived from n-cyclohexyl-2-phenoxynicotinamide; pharmaceutical composition comprising them; pharmaceutical combination comprising them; and its use to treat a disease mediated by pde4. | |
CL2008000202A1 (en) | Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain. | |
CL2007003587A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE TO TREAT OR PREVENT INFECTION OF HEPATITIS C. | |
CL2012003266A1 (en) | Tamarind seed polysaccharide for use in the treatment of microbial infections; pharmaceutical and / or antimicrobial dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide; method to treat and / or prevent a patient who has a microbial infection. | |
ZA201203689B (en) | A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent | |
MX2008015775A (en) | Compounds and compositions for treatment of cancer. | |
CL2009000964A1 (en) | Compounds derived from 1-aryl-2-imino-1,2-dihydropyridine-3-carboxamide, alpha 1d adrenergic receptor antagonist, pharmaceutical composition comprising them; and its use for the treatment or prophylaxis of diseases of the lower urinary tract. | |
EA201790383A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF INFECTIONS OF SURGERY INTERVENTION |